Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client
Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.
A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.
Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.
The earnings beat is the main new financial event driving the stock higher this period.
Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.
Raised guidance changes forward expectations, a key driver of the stock's move.
Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.
This is the real counterweight: a management change and high valuation could limit gains or add risk.